Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of antithrombin as prophylaxis of acute respiratory distress syndrome in patients with COVID-19
2020-001659-42Phase 2Completed
- Sponsor
- Fundación para la Investigación Biomédica de Córdoba
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of antithrombin III in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS), sponsored by Fundación para la Investigación Biomédica de Córdoba. Primary endpoint: Combined endpoint of mortality or respiratory worsening. Started Apr 2020; status: completed.
02
Drugs
antithrombin III
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-001659-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001659-42.